ResMed Stock Cut by Wolfe Due to Lilly GLP-1 Threat
Wednesday, 18 September 2024, 18:05
Market Implications of Wolfe's Downgrade
The recent downgrade of ResMed (RMD) by Wolfe highlights a critical turning point for the company amid Eli Lilly's (LLY) advancements in GLP-1 therapies. The concern centers on the potential label expansion for tirzepatide, which could directly impact ResMed's market share in obstructive sleep apnea treatments.
Analyst Insights
- Market analysts predict a challenging road ahead for ResMed if Lilly's drug gains traction.
- Investors are advised to monitor developments closely as the situation unfolds.
Potential Outcomes
- The expansion of GLP-1 drugs may lead to increased competition.
- ResMed's overall performance could be affected, prompting reevaluation of growth forecasts.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.